Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$7.3MCash on Hand
2mo Cash Runway
Follow JSPR by emailGet an email when JSPR reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about JSPR, unsubscribe in one click. Privacy
📣 What JSPR Says Is Next
fourth quarter of 2026 · Briquilimab: “Jasper is completing a Phase 1/2 case control study evaluating briquilimab as a conditioning agent for SCID patients receiving hematopoietic stem cell transplant. ○ The company expects to present initial data from the study in the fourth quarter of 2026.”
Company press release, Nov 16, 2026 · SEC filing
fourth quarter of 2026 · “Completed enrollment in first cohort of Phase 2 renal basket study evaluating vensobafusp alfa in IgA nephropathy. ○ Jasper expects to report interim IgAN data from Stage 1 of the renal basket study in the fourth quarter of 2026 and updated data in the first quarter of 2027.”
Company press release, Nov 16, 2026 · SEC filing
first quarter 2027 · “In addition, Jasper has accelerated the initiation of an additional cohort to the study evaluating vensobafusp alfa in focal segmental glomerulosclerosis (FSGS), with the first patient anticipated to be dosed in the first quarter 2027.”
Company press release, Oct 15, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 16, 2026 ·
Earnings Reported Q3 2026 results: cash and equivalents of $135.3 million, R&D expense of $8.3 million and G&A expense of $6.4 million. Completed enrollment in the IgA nephropathy cohort, with interim data expected in Q4 2026, and a 1-for-30 reverse stock split in November 2026. Form 8-K · SEC filing · Press release
Nov 16, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 13, 2026 ·
Shareholder vote Jasper Therapeutics adjourned its November 13, 2026 special stockholder meeting without conducting business because a quorum was not present. The meeting reconvenes December 1, 2026, at 10:00 a.m. Pacific Time, with no changes to the proposals. Form 8-K · SEC filing
Nov 9, 2026 ·
Jasper Therapeutics said holders tendered 8,510,658 warrants, about 68.94% of those outstanding, in its offer to buy them at $0.324 per warrant. The company expects to pay an aggregate of $2,757,453.19 in cash. Form 8-K · SEC filing · Press release
Oct 7, 2026 ·
Financing Jasper Therapeutics commenced an offer to buy any and all of its outstanding warrants at $0.324 cash per warrant, without interest. The warrants have a $2.92 exercise price and 12,345,707 are outstanding. The offer expires November 6, 2026, and would cost about $4.0 million if fully tendered. Form 8-K · SEC filing · Press release
Oct 5, 2026 ·
Jasper Therapeutics refiled Exhibit 99.3, the unaudited pro forma condensed combined financial information for its acquisition of Kira Pharmaceuticals, after a clerical error left an incomplete version in Amendment No. 1. Form 8-K/A · SEC filing · Press release
Oct 5, 2026 ·
Shareholder vote Stockholders approved three proposals at a September 30, 2026 special meeting: a reverse stock split at a ratio of 1-for-15 to 1-for-35 at the Board's discretion through December 31, 2026, an increase in authorized common stock from 490,000,000 to 675,000,000 shares, and an adjournment proposal. Form 8-K · SEC filing
Oct 1, 2026 ·
Deal Jasper Therapeutics files audited financial statements of Kira Pharmaceuticals for fiscal 2025 and 2024, plus unaudited six-month 2026 statements and pro forma combined financials tied to the Merger, a non-voting preferred financing, contingent value rights and the Mirador License Agreement. Form 8-K/A · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Dec 2026 · N/A · Recruiting · CO2 Reactivity as a Biomarker of Non-Response to Exposure-Based Therapy Registry primary completion date, not a results date
Jan 2027 · N/A · Recruiting · The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302) Registry primary completion date, not a results date
Jan 2027 · N/A · Recruiting · The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201) Registry primary completion date, not a results date
Jan 2028 · N/A · Recruiting · The PALSUR-study: Palliative Care Versus Surgery in High-grade Glioma Patients (ENCRAM 2203) Registry primary completion date, not a results date
Jan 2028 · N/A · Recruiting · The RESBIOP-study: Resection Versus Biopsy in High-grade Glioma Patients (ENCRAM 2202) Registry primary completion date, not a results date
Mar 2029 · Phase 3 · Recruiting · Community-based Smoking Cessation Treatment for Adults With High Stress Sensitivity. Registry primary completion date, not a results date
Also used in these trials (approved or third-party drugs, not JSPR's own candidates): Nicotine, Isradipine, Lomustine, Temozolomide.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
JSPR holds $7.3M in cash and short-term investments (as of Jun 30, 2026) and burns about $10.7M/quarter from operations,
an estimated runway of 2 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:80 · High
Cash runway 2 months +40
ATM program on file since Mar 2025 +15
Shelf registration (S-3, Mar 2025) +10
Going-concern doubt in the latest 10-Q +15The mitigating effect of the Company’s plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or…10-Q, Nov 2026
Share count 1,109,133 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full JSPR picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for JSPR and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.